Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.90 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.90 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.90 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.90 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.90 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | APEX1 | P27695 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxotremorine SCHEMBL2128 | 0.95 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11724836 | 0.93 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11726410 | 0.93 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11730865 | 0.93 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Oxotremorine SCHEMBL10532590 | 0.93 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11725498 | 0.93 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11726121 | 0.91 | CHRM2 (0.93) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL31263727 | 0.91 | CHRM2 (0.93) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11721410 | 0.89 | CHRM2 (0.89) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11727343 | 0.89 | CHRM2 (0.89) | CHRM2CHRM5CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328261-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | Minerva Biotechnologies Corporation (US) | 2003-07-23 | — | — | EP | claimed |
| US-20030060487-A1 | Treatment of neurodegenerative disease | MINERVA BIOTECHNOLOGIES CORPORATION | 2003-03-27 | — | — | US | claimed |
| WO-2001078709-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200390780-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2020-12-17 | — | — | US | disclosed |
| US-20200163936-A1 | Oxo-M and 4-PPBP induction of tenogenic differentiation of perivascular tendon stem cells | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-05-28 | — | — | US | disclosed |
| US-20200163936-A1 | Oxo-M and 4-PPBP induction of tenogenic differentiation of perivascular tendon stem cells | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-05-28 | — | — | US | disclosed |
| US-10660899-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-05-26 | — | — | US | disclosed |
| US-10583117-B2 | Oxo-M and 4-PPBP induction of tenogenic differentiation of perivascular tendon stem cells | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-10 | — | — | US | disclosed |
| US-10583117-B2 | Oxo-M and 4-PPBP induction of tenogenic differentiation of perivascular tendon stem cells | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190015386-A1 | Oxo-M and 4-PPBP induction of tenogenic differentiation of perivascular tendon stem cells | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-01-17 | — | — | US | disclosed |
| US-7288630-B2 | Potassium channel KCNQ5 and sequences encoding the same | NEUROSEARCH A/S (DK) | 2007-10-30 | — | — | US | disclosed |
| EP-1194447-B1 | NOVEL POTASSIUM CHANNELS AND GENES ENCODING THESE POTASSIUM CHANNELS | NEUROSEARCH AS (DK) | 2007-09-26 | — | — | EP | disclosed |
| US-20040180405-A1 | Novel potassium channels and genes encoding these potassium channels | NEUROSEARCH A/S | 2004-09-16 | — | — | US | disclosed |
| US-6649371-B1 | Isolated nucleic acid molecule; using transformed cells for screening compounds for inhibiting or activating activity | NEUROSEARCH A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| EP-1328261-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | Minerva Biotechnologies Corporation (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030060487-A1 | Treatment of neurodegenerative disease | MINERVA BIOTECHNOLOGIES CORPORATION | 2003-03-27 | — | — | US | disclosed |
| EP-1194447-A2 | NOVEL POTASSIUM CHANNELS AND GENES ENCODING THESE POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001078709-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2000077035-A2 | NOVEL POTASSIUM CHANNELS AND GENES ENCODING THESE POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060487-A1 | Treatment of neurodegenerative disease | HTT, IAPP, APP | CHRM2 3018/4885CHRM5 1972/4885CHRM1 3695/4885 |
| US-20190015386-A1 | Oxo-M and 4-PPBP induction of tenogenic differentiation of perivascular tendon stem cells | MTPN, BMP4, TTN | CHRM2 1178/4885CHRM5 501/4885CHRM1 1631/4885 |
| US-20200163936-A1 | Oxo-M and 4-PPBP induction of tenogenic differentiation of perivascular tendon stem cells | MTPN, BMP4, TTN | CHRM2 1178/4885CHRM5 501/4885CHRM1 1631/4885 |
| US-10583117-B2 | Oxo-M and 4-PPBP induction of tenogenic differentiation of perivascular tendon stem cells | MTPN, BMP4, TTN | CHRM2 1178/4885CHRM5 501/4885CHRM1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.